{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:35:04Z","timestamp":1776850504757,"version":"3.51.2"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>Neonatal drug utilization in very premature infants (gestational age (GA) 24-29\nweeks), requiring intubation and mechanical ventilation at birth was registered as part of a\nmulticenter controlled clinical trial of high-dose versus low-dose bovine surfactant (initial\ndoses 100 mg\/kg birth weight (b.w.) versus 50 mg\/kg b.w.). Drug utilization during 4 weeks\nafter birth was analyzed in 164 infants (mean GA 27.2 \u00b1 1.2 (SD) weeks, b.w. 970 \u00b1 145 g\n(SD)). More than half of the study infants received antibiotics (98.8%), sedatives and analgesics\n(91.5%), sodium bicarbonate (78%), solutions for volume replacement (62.8%), methylxanthines\n(56.7%) and catecholamines (52.4%). It may be concluded that the pattern of\ndrug usage indicates a high incidence of proven or suspected infections and circulatory and\nrespiratory disorders reflecting the high-risk state of study infants.<\/jats:p>","DOI":"10.1159\/000457518","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:08:32Z","timestamp":1502471312000},"page":"167-171","source":"Crossref","is-referenced-by-count":7,"title":["Drug Utilization in Very Premature Infants in Neonatal\nIntensive Care Units"],"prefix":"10.1159","author":[{"given":"L.","family":"Gortner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Bernsau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Brand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.H.","family":"Hellwege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Hieronimie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Jorch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.L.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.I.","family":"Versmold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:34:47Z","timestamp":1776846887000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457518","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}